Discover my current regimen (since August 2015) more info

Review of What’s Known About Psoriasis

Book Extract

This article is an extract from: Seborrheic Dermatitis - The Owner's Manual; a book dedicated to understanding seborrheic dermatitis. See the book overview page for more information.

  • Chronic Skin Condition: Psoriasis is a persistent skin issue with recurring episodes.
  • Immune System Link: It’s an autoimmune condition rooted in how your body’s defenses work.
  • Varied Symptoms: From scalp issues to nail changes and joint pain, psoriasis manifests differently.
  • Multiple Types: Plaque, guttate, pustular, and more – each type has distinct features.
  • Treatment Options: Topical creams, light therapy, and systemic medications are among the treatments available.

Psoriasis is a chronic skin condition characterized by relapses, sharing similarities with seborrheic dermatitis. Considered a genetically influenced condition, its onset and flare-ups are often linked to environmental and immunological factors [1].

Like seborrheic dermatitis, psoriasis is widespread, affecting an estimated 2-3% of the global population [2]. Among those with psoriasis, about 25% experience moderate to severe symptoms [3].

Psoriasis can appear on localized areas, such as the scalp, or spread across larger portions of the body. Commonly affected areas include the scalp, fingertips and toes, palms, soles, belly button, buttocks, under the breasts, genitals, elbows, knees, shins, and lower back [4]. Scalp psoriasis is particularly prevalent, affecting 75-90% of psoriasis patients [5].

Image for Understanding Psoriasis

Understanding Psoriasis

Psoriasis is fundamentally an immune-related skin disease, connected to irregularities in immune function [6, 7, 8]. The likelihood of developing psoriasis also increases as we age [9].

Many symptoms overlap with seborrheic dermatitis:

  • Skin inflammation patches
  • Silvery scales
  • Dry, cracked skin
  • Itching, burning, or tingling sensations

However, psoriasis uniquely involves abnormal epidermal differentiation and hyper-proliferation of skin cells.

Healthy skin cells typically take about 48 days to mature and reach the surface. In psoriasis, this process accelerates dramatically to just 6-8 days [10]. This rapid turnover leads to the buildup of skin cells on the surface, forming plaques.

Besides plaques, itching is a hallmark of psoriasis. In fact, the term “psoriasis” originates from the Greek word “psora,” meaning itch.

Immune System Dysfunction and Inflammation

The prevailing theory suggests that psoriasis symptoms arise from faulty communication between the innate and adaptive immune systems [2].

Research indicates that overactive T cells in the skin trigger inflammation, recruit more inflammatory cells, and accelerate skin cell division. This combination of events culminates in the characteristic symptoms of psoriasis.

Some researchers even propose considering psoriasis not just as a skin condition, but as a systemic inflammatory disorder affecting the whole body [2, 11, 12].

Associated Health Issues

While the physical discomfort of psoriasis, such as itching and burning, is significant, many individuals find the psychological impact even more challenging. The visible nature of psoriasis can lead to negative reactions from others and feelings of embarrassment, profoundly affecting social interactions and potentially causing social isolation and depression.

Studies comparing quality of life across chronic conditions, including cancer, reveal that only depression and chronic lung disease impact quality of life more negatively than psoriasis [13].

Furthermore, metabolic syndrome and cardiovascular disease are more common in people with psoriasis, adding to the overall health burden [14, 15]. It’s crucial for individuals with psoriasis to be aware of these potential links and proactively manage these aspects to prevent broader health complications.

Beyond depression, metabolic syndrome, and cardiovascular disease, psoriasis has been linked to several other conditions []:

  • Anxiety
  • Non-alcoholic fatty liver disease
  • Crohn’s disease
  • Lymphoma

Image for Types of Psoriasis

Types of Psoriasis

Psoriasis presents in several forms, and these types can sometimes overlap, making accurate diagnosis essential for effective treatment planning. While visual examination is a starting point, skin biopsies can offer a more precise diagnosis.

Plaque Psoriasis (Psoriasis Vulgaris)

Plaque Psoriasis

Plaque psoriasis, also known as psoriasis vulgaris, is the most frequent type, accounting for about 90% of all cases.

It’s characterized by the excessive production of skin cells, leading to their accumulation on the skin’s surface. This results in raised patches of dead skin, known as plaques.

Key symptoms include inflammation, scales on the skin (varying in size and distribution), and itching.

While typically not life-threatening, extensive plaque psoriasis covering large areas can become dangerous due to excessive moisture loss. However, life-threatening situations are more often related to side effects from systemic medications used for treatment [16].

Plaque Psoriasis = Psoriasis Vulgaris
Plaque psoriasis is also known as psoriasis vulgaris.

Inverse/Flexural Psoriasis

Inverse or flexural psoriasis is a subtype of plaque psoriasis that develops in skin folds and areas of friction, such as armpits, under breasts, and between buttocks.

Scales are less common in this type due to moisture and friction in these areas hindering their formation. Instead, redness and inflammation are more prominent.

Scalp Psoriasis

Scalp psoriasis is essentially plaque psoriasis affecting the scalp.

It’s distinguished by thicker, denser plaques compared to those on other body areas. Scales often adhere to hair shafts, leading to noticeable shedding, even without scratching.

Hair loss (alopecia) can occur if plaques accumulate and damage hair follicles [17]. Fortunately, hair loss is usually temporary.

Severe Cases of Scalp Psoriasis
Severe scalp psoriasis with very thick, dense scales may be diagnosed as pityriasis amiantacea [18].

Erythrodermic Psoriasis

Erythrodermic psoriasis is an aggressive form where inflammation affects most of the skin surface. It often arises from a sudden worsening of existing plaque psoriasis, sometimes triggered by abruptly stopping systemic treatments [19, 20]. This is a severe but less common form of psoriasis.

Nail Psoriasis

Nail Psoriasis

Nail psoriasis affects the fingernails and toenails, causing:

  • Pitting (small depressions) on the nail surface
  • Yellowish or brownish patches under the nails
  • Thickening of the skin beneath the nails

In severe cases, nails can thicken, crumble, and even detach, causing significant impairment.

About half of those with plaque psoriasis will experience nail psoriasis at some point [21]. Nail psoriasis rarely occurs without a history of other forms of psoriasis.

Psoriatic Arthritis

Psoriatic arthritis is related to psoriasis but primarily involves joint inflammation and connective tissue issues. It’s not a skin condition, but it’s strongly linked to psoriasis.

It can affect any joint, but fingers and toes are most commonly involved [22].

While it affects only a small percentage of the general population (0.3-3%), the risk is much higher for individuals with psoriasis (10-15%) [23, 24].

Symptoms range from mild to severe, significantly impacting quality of life in some individuals [23].

Guttate Psoriasis

Guttate Psoriasis

Guttate psoriasis is characterized by small, tear-drop shaped, scaly spots appearing across the body. Sometimes, it may be limited to certain areas.

Lesions are typically concentrated on the torso, thighs, and upper arms. The scalp, face, and ears can also be affected, though lesions there are usually less severe [25].

Often, guttate psoriasis is triggered by streptococcal infections, like strep throat, and can sometimes resolve on its own [26, 27].

Pustular Psoriasis

Pustular psoriasis is distinguished by pustules (blisters) filled with white pus. It often has a rapid onset, with pustules appearing within hours during flare-ups.

Interestingly, some cases are linked to tumor necrosis factor medications and systemic steroid use (corticosteroids), treatments typically used for less severe psoriasis [28, 29, 30].

Sub-Types of Pustular Psoriasis
Pustular psoriasis has further subtypes based on specific criteria like overlap with psoriasis vulgaris, pustule location, and pus production, but these are beyond this discussion.

Sebopsoriasis

Sebopsoriasis is not a distinct psoriasis type but describes the co-occurrence of both psoriasis and seborrheic dermatitis. It primarily affects sebum-rich areas common in seborrheic dermatitis.

Image for Common Psoriasis Triggers and Risk Factors

Common Psoriasis Triggers and Risk Factors

Many factors can trigger psoriasis flare-ups or increase the risk of developing the condition. Understanding these can aid in management and prevention.

Emotional Stress

Stress and depression are well-known triggers for various skin conditions, including acne, alopecia, atopic dermatitis, seborrheic dermatitis, rosacea, and psoriasis [31, 32, 33].

In psoriasis, emotional stress appears to be a particularly significant factor [34, 35]. Some research even suggests stress can play a crucial role in the initial onset of psoriasis in susceptible individuals [31].

Skin Injury (Koebner Phenomenon)

While skin damage may not directly cause psoriasis, injured skin becomes more vulnerable to developing psoriasis symptoms in predisposed individuals [36, 37].

Koebner phenomenon
Skin injury as a psoriasis trigger is known as the Koebner phenomenon, also seen in other skin conditions.

Common skin injuries include:

  • Scratching
  • Tattoos
  • Piercings
  • Sunburn
  • Chemical irritants
  • Burns
  • Trauma

Considering all factors
Work environments with airborne irritants, such as hair salons, workshops, and factories, can cause ongoing skin damage and increase psoriasis risk.

Systemic Infections

Similar to seborrheic dermatitis, HIV infection increases the likelihood of developing psoriasis [38]. HIV itself doesn’t cause psoriasis, but it raises the risk in those already susceptible [38].

Abnormal T-cell activity and altered immune function are believed to be underlying factors [39, 40].

Medications

Certain medications can trigger or worsen psoriasis. Awareness of these culprits can help in medication management.

Beta Blockers

Beta blockers, used for heart conditions, hyperthyroidism, anxiety, and glaucoma, have been linked to psoriasis in some cases, particularly propranolol [41, 42].

However, some studies dispute this link, suggesting the skin issues might be similar but different dermatological conditions [43] or finding no association [44].

Regardless, considering beta-blockers as a potential trigger may be worthwhile. Discontinuation has led to symptom clearance in some cases within weeks [45].

Lithium

Lithium, used for depression and mental disorders, can trigger or worsen psoriasis in some individuals [46]. While the risk of lithium causing psoriasis is relatively low, its impact on existing psoriasis can be significant.

Symptoms may appear 20 to 48 weeks after starting lithium, potentially masking the connection.

Lithium medication side-effects Lithium can have toxic effects on various organs, including the skin, thyroid, kidneys, central nervous system, and gastrointestinal tract, potentially causing acne-like eruptions and alopecia in addition to psoriasis [47].

Antimalarials

Antimalarial drugs, also used for psoriatic arthritis and lupus, have been reported to worsen existing psoriasis in some instances [id=”114043006,3346150″].

Corticosteroids

Corticosteroids, while effective for many skin disorders including psoriasis, can cause rebound flares if long-term use is abruptly stopped, potentially worsening psoriasis symptoms [48]. Long-term use also carries risks of various side effects [49, 50].

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

NSAIDs, commonly prescribed for pain and inflammation, have been linked to worsening psoriasis symptoms in some individuals [], often without people realizing the connection [47].

Intestinal Issues

Digestive issues frequently accompany psoriasis, including inflammatory bowel disease, Crohn’s disease, ulcerative colitis, and celiac disease [51, 52].

Examples of intestinal issues in psoriasis patients include:

  • Inflammatory changes in the colon [53]
  • Altered gut microbiota and reduced bacterial diversity [54]
  • Increased intestinal permeability (“leaky gut”) [55]

While the causal relationship is unclear, shared immune system irregularities likely play a role, and understanding these may lead to new treatments.

Diet

Psoriasis patients often have diets low in fruits, vegetables, and fiber, and high in refined carbohydrates and unhealthy fats [56].

Lipid abnormalities and diets high in pro-inflammatory omega-6 fatty acids are also suspected contributors to psoriasis severity [57, 58].

Lifestyle Habits

Smoking and alcohol consumption can increase psoriasis risk [59, 60]. While some conflicting data exists, reducing these habits is generally believed to improve psoriasis.

Alcohol Abuse

Evidence linking alcohol to psoriasis is strongest for [61, 62]:

  • Moderate to high alcohol consumption
  • Males more than females

However, as alcohol use can be a stress response, some argue it may be a consequence of living with psoriasis-related stress [63, 64].

Regardless, heavy alcohol intake worsens psoriasis symptoms [65], and abstinence has been linked to remission in some cases [66].

Alcohol’s negative impacts on immune function, inflammation, liver function, and T-cell activity are potential mechanisms for worsening psoriasis [67, 68, 69, 70].

Smoking

Smokers are significantly more prevalent among psoriasis sufferers than the general population, even considering those who started smoking after psoriasis onset [71].

One study suggested smoking could trigger up to 25% of psoriasis cases [72], although this was published in 1993 when smoking rates were higher.

Quitting smoking after psoriasis develops doesn’t seem to improve symptoms [73].

The overlap between smoking and other unhealthy habits complicates isolating smoking as a sole factor [74, 75].

Possible mechanisms for smoking’s influence on psoriasis include nicotine’s effect on skin cell differentiation [76] and oxidative damage [77, 78].

Seasonal Factors

Similar to seborrheic dermatitis, psoriasis and psoriatic arthritis often worsen in winter and improve in summer [79], potentially due to reduced UV exposure and lower vitamin D levels.

Image for Psoriasis Treatment Strategies

Psoriasis Treatment Strategies

Psoriasis treatments largely aim to manage symptoms by targeting:

  1. Immune modulation
  2. Normalization of skin cell (keratinocyte) differentiation

Immune-modulating treatments often indirectly improve skin cell differentiation as well, leading to more significant relief but potentially with greater side effect risks.

Mild cases may respond to treatments focused solely on normalizing skin cell differentiation.

Topical Treatments

Corticosteroids and Vitamin D derivatives are established topical treatments for moderate psoriasis [2], often used in combination for enhanced effectiveness [80].

Combining treatments can improve efficacy and reduce side effects by lowering the concentration of individual agents.

Topical therapies typically show initial improvements within 2-3 weeks, starting with scale clearance, followed by plaque resolution, and gradual inflammation reduction over 6-8 weeks.

However, potential side effects and the effort of consistent application remain challenges with topical treatments.

A brief overview of common topical treatments:

Corticosteroids (Topical)

Topical corticosteroids are the most frequently prescribed medication for plaque psoriasis [].

They suppress local immune response, reduce inflammation, and normalize skin cell turnover [81, 82].

Potency varies among corticosteroids, with stronger options being more effective but carrying a higher risk of side effects [83].

Long-term use can lead to skin thinning (atrophy), spider veins, stretch marks, and other skin issues [84, 85]. The long-term risks need careful consideration for chronic conditions like psoriasis.

Vitamin D Derivatives (Topical)

Vitamin D derivatives like calcipotriene, calcipotriol, and calcitriol are highly effective, often superior to coal tar, hydrocortisone, anthralin, and betamethasone valerate [83, 86].

They bind to vitamin D receptors in skin cells, regulating cell turnover, reducing inflammation, and inhibiting T-cell activity [87, 88, 89, 90].

They generally have a good safety profile with fewer adverse effects reported compared to corticosteroids [91, 92, 93, 94].

Coal Tar (Topical)

Coal tar is one of the oldest psoriasis treatments, also used for other skin conditions like seborrheic dermatitis [95].

Its established safety and effectiveness in moderate psoriasis make it suitable for long-term use [96, 97]. However, its messiness, odor, application challenges, and limited efficacy in severe cases prompt many to seek alternatives [98, 99].

Coal tar’s benefits may stem from suppressing DNA synthesis, reducing keratinization [100], and its anti-inflammatory and antimicrobial properties [101].

Anthralin (Topical)

Anthralin is a synthetic medication that inhibits cell growth and reduces keratinocyte formation [102].

It’s as effective as potent corticosteroids, but its use is limited by skin irritation and staining [103].

Tazarotene (Topical)

Tazarotene, a synthetic retinoid, reduces inflammation and epidermal cell production [].

Effective for psoriasis, its efficacy can be enhanced when combined with corticosteroids [104, 105]. Skin irritation can limit its use, similar to anthralin.

Salicylic Acid (Topical)

Salicylic acid, from willow bark, promotes shedding of the outer skin layer, improving skin appearance [106, 107]. It also has antimicrobial, antifungal properties and can lower skin pH [108].

Salicylic acid alone is usually insufficient for psoriasis treatment and is often combined with corticosteroids or betamethasone dipropionate [109]. It can enhance penetration of other active ingredients, improving treatment outcomes.

Phototherapy (Light Therapy)

Controlled UV light exposure is a proven treatment for psoriasis. Narrow-band UVB and broadband UVB phototherapy are both effective [110].

High clearance rates, even in severe cases, make phototherapy a valuable option for long-term management. However, safety considerations exist.

While some studies suggest increased skin cancer risk with long-term PUVA treatment [111, 112], a 25-year study of broadband UVB and coal tar (which increases UV sensitivity) found no such link [113].

Focus on PUVA PUVA therapy involves a photosensitizing medication, increasing UV sensitivity and potentially explaining the higher skin cancer risk seen with this specific type of phototherapy.

Excessive UV exposure is generally known to increase skin cancer risk [114].

Combining or rotating phototherapy with topical treatments may minimize risks [115, 116]. Controlled and monitored therapy regimens are key to safety.

Simple sun exposure Natural sunlight exposure can improve psoriasis for many, though benefits vary by location and sun intensity [117, 118].

Light therapy’s benefits are believed to stem from UV light’s damaging effects on skin cells and its immunosuppressive properties [119], helping to reduce skin cell proliferation and modulate inflammatory T-cell responses.

Systemic Medications

Systemic medications, affecting the entire body, can be highly effective for psoriasis. These include immune-suppressing drugs, synthetic retinoids, and fumaric acid esters [120].

Most systemic psoriasis medications (except fumaric acid esters) carry risks of organ toxicities and significant side effects [2, 121]. Therefore, they are generally considered when other treatments have failed.

Natural Remedies

Due to growing interest in natural treatments, herbal remedies are explored for psoriasis. However, research funding for herbal treatments is often limited, and evidence is often less robust.

Some notable natural options include:

  • Capsaicin: Topical capsaicin cream (from cayenne peppers) has shown promise for moderate to severe psoriasis in limited studies [122, 123].
  • Aloe Vera: A study in Pakistan indicated 0.5% aloe vera cream may help moderate plaque psoriasis, with high healing rates [124], but a later study contradicted these findings [125].
  • Milk Thistle: Anecdotal evidence suggests milk thistle may aid psoriasis by improving liver function [135]. Silymarin extracts (from milk thistle) are approved in Germany for liver disease [126], and liver health is relevant to overall psoriasis management.
  • Curcumin: Curcumin (from turmeric) is proposed to have anti-inflammatory benefits for psoriasis. Initial research showed limited effectiveness overall [127], but some individuals in the study experienced excellent results.

Dietary Adjustments

Given psoriasis’s chronic nature, dietary changes offer a potential long-term approach to address the underlying issues. However, lack of strong evidence for specific diets and individual variability make this approach complex.

The following dietary approaches have shown benefits for both psoriasis symptoms and related cardiovascular issues [58]:

  • Intermittent fasting
  • Calorie restriction
  • Reduced meat and animal fat intake
  • Increased omega-3 fatty acid intake

These diets are thought to reduce inflammation due to lower omega-6 fatty acid intake.

Image for Key Takeaways: Psoriasis Explained

Key Takeaways: Psoriasis Explained

This review provides a detailed overview of psoriasis to differentiate it from seborrheic dermatitis and inform treatment decisions.

Here are the key points to remember:

  1. Psoriasis is a chronic inflammatory skin condition, similar to seborrheic dermatitis, marked by inflammation, plaques, itching, and relapses. Unlike seborrheic dermatitis, psoriasis can affect any skin area.
  2. It’s considered a genetically influenced autoimmune disease triggered by environmental factors, with symptoms primarily resulting from accelerated skin cell division.
  3. Plaque psoriasis is the most common type, but other types exist, each requiring tailored treatment approaches.
  4. Key psoriasis types include guttate (tear-drop spots), pustular (pus-filled blisters), and psoriatic arthritis (joint inflammation).
  5. Stress, skin injury, infections, certain medications, intestinal issues, poor diet, and unhealthy lifestyle habits are identified risk factors and can worsen symptoms.
  6. Treatments mainly target immune modulation and/or slowing down skin cell division.
  7. Topical corticosteroids are effective and commonly used but carry risks with long-term use.
  8. Vitamin D derivatives and phototherapy are comparably effective with potentially lower risks than corticosteroids when properly used.
  9. Natural treatment options include capsaicin creams, coal tar, sunlight exposure, and anti-inflammatory diets.

Book Extract

This article is an extract from: Seborrheic Dermatitis - The Owner's Manual; a book dedicated to understanding seborrheic dermatitis. See the book overview page for more information.

References

  1. Paola Di Meglio, Federica Villanova, Frank O Nestle "Psoriasis." Cold Spring Harbor perspectives in medicine 4.8 (2015). PubMed
  2. Wolf-Henning Boehncke, Michael P Schön "Psoriasis." Lancet (London, England) 386.9997 (2015): 983-94. PubMed
  3. B Lindelöf, G Eklund, S Lidén, R S Stern "The prevalence of malignant tumors in patients with psoriasis." Journal of the American Academy of Dermatology 22.6 Pt 1 (1990): 1056-60. PubMed
  4. E M Farber, M L Nall "The natural history of psoriasis in 5,600 patients." Dermatologica 148.1 (1974): 1-18. PubMed
  5. Jp Ortonne, S Chimenti, T Luger, L Puig, F Reid, R M Trüeb "Scalp psoriasis: European consensus on grading and treatment algorithm." Journal of the European Academy of Dermatology and Venereology : JEADV 23.12 (2010): 1435-44. PubMed
  6. Jaehwan Kim, James G Krueger "The immunopathogenesis of psoriasis." Dermatologic clinics 33.1 (2015): 13-23. PubMed
  7. Robert Sabat, Sandra Philipp, Conny Höflich, Stefanie Kreutzer, Elizabeth Wallace, Khusru Asadullah, Hans-Dieter Volk, Wolfram Sterry, Kerstin Wolk "Immunopathogenesis of psoriasis." Experimental dermatology 16.10 (2007): 779-98. PubMed
  8. R K H Mak, C Hundhausen, F O Nestle "Progress in understanding the immunopathogenesis of psoriasis." Actas dermo-sifiliograficas 100 Suppl 2 (2010): 2-13. PubMed
  9. M Augustin, G Glaeske, M A Radtke, E Christophers, K Reich, I Schäfer "Epidemiology and comorbidity of psoriasis in children." The British journal of dermatology 162.3 (2010): 633-6. PubMed
  10. K M Halprin "Epidermal “turnover time”–a re-examination." The British journal of dermatology 86.1 (1972): 14-9. PubMed
  11. Christopher E M Griffiths, Jonathan N W N Barker "Pathogenesis and clinical features of psoriasis." Lancet (London, England) 370.9583 (2007): 263-71. PubMed
  12. Caitriona Ryan, Brian Kirby "Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities." Dermatologic clinics 33.1 (2015): 41-55. PubMed
  13. S R Rapp, S R Feldman, M L Exum, A B Fleischer, D M Reboussin "Psoriasis causes as much disability as other major medical diseases." Journal of the American Academy of Dermatology 41.3 Pt 1 (1999): 401-7. PubMed
  14. Joel M Gelfand, Howa Yeung "Metabolic syndrome in patients with psoriatic disease." The Journal of rheumatology. Supplement 89 (2012): 24-8. PubMed
  15. Tanmay Padhi "Metabolic syndrome and skin: psoriasis and beyond." Indian journal of dermatology 58.4 (2013): 299-305. PubMed
  16. Proton Rahman, Robert D Inman, Walter P Maksymowych, Jeff P Reeve, Lynette Peddle, Dafna D Gladman "Association of interleukin 23 receptor variants with psoriatic arthritis." The Journal of rheumatology 36.1 (2009): 137-40. PubMed
  17. P C van de Kerkhof, M E Franssen "Psoriasis of the scalp. Diagnosis and management." American journal of clinical dermatology 2.3 (2001): 159-65. PubMed
  18. C J van der Vleuten, P C van de Kerkhof "Management of scalp psoriasis: guidelines for corticosteroid use in combination treatment." Drugs 61.11 (2002): 1593-8. PubMed
  19. U Runne, P Kroneisen-Wiersma "Psoriatic alopecia: acute and chronic hair loss in 47 patients with scalp psoriasis." Dermatology (Basel, Switzerland) 185.2 (1992): 82-7. PubMed
  20. D Creamer, M H Allen, R W Groves, J N Barker "Circulating vascular permeability factor/vascular endothelial growth factor in erythroderma." Lancet (London, England) 348.9034 (1996): 1101. PubMed
  21. K Reich "Approach to managing patients with nail psoriasis." Journal of the European Academy of Dermatology and Venereology : JEADV 23 Suppl 1 (2009): 15-21. PubMed
  22. Ilaria Ruffilli, Francesca Ragusa, Salvatore Benvenga, Roberto Vita, Alessandro Antonelli, Poupak Fallahi, Silvia Martina Ferrari "Psoriasis, Psoriatic Arthritis, and Thyroid Autoimmunity." Frontiers in endocrinology 8 (2017): 139. PubMed
  23. D D Gladman, C Antoni, P Mease, D O Clegg, P Nash "Psoriatic arthritis: epidemiology, clinical features, course, and outcome." Annals of the rheumatic diseases 64 Suppl 2 (2005): ii14-7. PubMed
  24. G Ibrahim, R Waxman, P S Helliwell "The prevalence of psoriatic arthritis in people with psoriasis." Arthritis and rheumatism 61.10 (2009): 1373-8. PubMed
  25. R G B Langley, G G Krueger, C E M Griffiths "Psoriasis: epidemiology, clinical features, and quality of life." Annals of the rheumatic diseases 64 Suppl 2 (2005): ii18-23; discussion ii24-5. PubMed
  26. D Y Leung, J B Travers, R Giorno, D A Norris, R Skinner, J Aelion, L V Kazemi, M H Kim, A E Trumble, M Kotb "Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis." The Journal of clinical investigation 96.5 (1995): 2106-12. PubMed
  27. H J WHYTE, R D BAUGHMAN "ACUTE GUTTATE PSORIASIS AND STREPTOCOCCAL INFECTION." Archives of dermatology 89 (1996): 350-6. PubMed
  28. Eugenia Shmidt, David A Wetter, Sara B Ferguson, Mark R Pittelkow "Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010." Journal of the American Academy of Dermatology 67.5 (2013): e179-85. PubMed
  29. Caroline Joyau, Gwenaelle Veyrac, Veronique Dixneuf, Pascale Jolliet "Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?" Clinical and experimental rheumatology 30.5 (2013): 700-6. PubMed
  30. Danielle Cristine Westphal, Antonio Pedro Mendes Schettini, Petra Pereira de Souza, Jessica Castiel, Carlos Alberto Chirano, Mônica Santos "Generalized pustular psoriasis induced by systemic steroid dose reduction." Anais brasileiros de dermatologia 91.5 (2017): 664-666. PubMed
  31. M S Al'Abadie, G G Kent, D J Gawkrodger "The relationship between stress and the onset and exacerbation of psoriasis and other skin conditions." The British journal of dermatology 130.2 (1994): 199-203. PubMed
  32. I Sowińska-Gługiewicz, V Ratajczak-Stefańska, R Maleszka "Role of psychological factors in course of the rosacea." Roczniki Akademii Medycznej w Bialymstoku (1995) 50 Suppl 1 (2005): 49-53. PubMed
  33. L Misery, S Touboul, C Vinueot, S Dutray, G Rolland-Jacob, S-G Consoli, Y Farcet, N Feton-Danou, F Cardinaud, V Callot, C De La Chapelle, D Pomey-Rey, S-M Consoli "[Stress and seborrheic dermatitis]." Annales de dermatologie et de venereologie 134.11 (2007): 833-7. PubMed
  34. Shanu Kohli Kurd, Andrea B Troxel, Paul Crits-Christoph, Joel M Gelfand "The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study." Archives of dermatology 146.8 (2010): 891-5. PubMed
  35. H Devrimci-Ozguven, T N Kundakci, H Kumbasar, A Boyvat "The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients." Journal of the European Academy of Dermatology and Venereology : JEADV 14.4 (2001): 267-71. PubMed
  36. Yvonne Dabota Buowari "Clinical presentation and management of schistosomiasis at a hospital in a rural area in Nigeria." Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria 20.1 (2011): 61-4. PubMed
  37. Aylin Kalayciyan, Ertugrul H Aydemir, Agop Kotogyan "Experimental Koebner phenomenon in patients with psoriasis." Dermatology (Basel, Switzerland) 215.2 (2007): 114-7. PubMed
  38. Nilesh Morar, Saffron A Willis-Owen, Toby Maurer, Christopher B Bunker "HIV-associated psoriasis: pathogenesis, clinical features, and management." The Lancet. Infectious diseases 10.7 (2010): 470-8. PubMed
  39. C Garbe, R Husak, C E Orfanos "[HIV-associated dermatoses and their prevalence in 456 HIV-infected patients. Relation to immune status and its importance as a diagnostic marker]." Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 45.9 (1994): 623-9. PubMed
  40. E Mallon, C B Bunker "HIV-associated psoriasis." AIDS patient care and STDs 14.5 (2000): 239-46. PubMed
  41. Mehmet Birhan Yilmaz, Hasan Turhan, Yesim Akin, Halil L Kisacik, Sule Korkmaz "Beta-blocker-induced psoriasis: a rare side effect–a case report." Angiology 53.6 (2002): 737-9. PubMed
  42. A D Cohen, M Kagen, M Friger, S Halevy "Calcium channel blockers intake and psoriasis: a case-control study." Acta dermato-venereologica 81.5 (2002): 347-9. PubMed
  43. M C Heng, M K Heng "Beta-adrenoceptor antagonist-induced psoriasiform eruption. Clinical and pathogenetic aspects." International journal of dermatology 27.9 (1989): 619-27. PubMed
  44. Y B Brauchli, S S Jick, F Curtin, C R Meier "Association between beta-blockers, other antihypertensive drugs and psoriasis: population-based case-control study." The British journal of dermatology 158.6 (2008): 1299-307. PubMed
  45. S Halevy, E J Feuerman "Psoriasiform eruption induced by propranolol." Cutis 24.1 (1979): 95-8. PubMed
  46. Franco Rongioletti, Cristina Fiorucci, Aurora Parodi "Psoriasis induced or aggravated by drugs." The Journal of rheumatology. Supplement 83 (2009): 59-61. PubMed
  47. E A Abel, L M DiCicco, E K Orenberg, J E Fraki, E M Farber "Drugs in exacerbation of psoriasis." Journal of the American Academy of Dermatology 15.5 Pt 1 (1987): 1007-22. PubMed
  48. L Hellgren "Induction of generalized pustular psoriasis by topical use of betamethasone-dipropionate ointment in psoriasis." Annals of clinical research 8.5 (1977): 317-9. PubMed
  49. Heike Schäcke, Wolf Dietrich Döcke, Khusru Asadullah "Mechanisms involved in the side effects of glucocorticoids." Pharmacology & therapeutics 96.1 (2003): 23-43. PubMed
  50. A L Buchman "Side effects of corticosteroid therapy." Journal of clinical gastroenterology 33.4 (2001): 289-94. PubMed
  51. Paolo Gisondi, Micol Del Giglio, Alessandra Cozzi, Giampiero Girolomoni "Psoriasis, the liver, and the gastrointestinal tract." Dermatologic therapy 23.2 (2010): 155-9. PubMed
  52. V M Yates, G Watkinson, A Kelman "Further evidence for an association between psoriasis, Crohn’s disease and ulcerative colitis." The British journal of dermatology 106.3 (1982): 323-30. PubMed
  53. R Scarpa, F Manguso, A D'Arienzo, F P D'Armiento, C Astarita, G Mazzacca, F Ayala "Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms." The Journal of rheumatology 27.5 (2000): 1241-6. PubMed
  54. Jose U Scher, Carles Ubeda, Alejandro Artacho, Mukundan Attur, Sandrine Isaac, Soumya M Reddy, Shoshana Marmon, Andrea Neimann, Samuel Brusca, Tejas Patel, Julia Manasson, Eric G Pamer, Dan R Littman, Steven B Abramson "Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease." Arthritis & rheumatology (Hoboken, N.J.) 67.1 (2015): 128-39. PubMed
  55. P Humbert, A Bidet, P Treffel, C Drobacheff, P Agache "Intestinal permeability in patients with psoriasis." Journal of dermatological science 2.4 (1991): 324-6. PubMed
  56. S Zamboni, G Zanetti, G Grosso, G B Ambrosio, S Gozzetti, A Peserico "Dietary behaviour in psoriatic patients." Acta dermato-venereologica. Supplementum 146 (1990): 182-3. PubMed
  57. Lotus Mallbris, Fredrik Granath, Anders Hamsten, Mona Ståhle "Psoriasis is associated with lipid abnormalities at the onset of skin disease." Journal of the American Academy of Dermatology 54.4 (2006): 614-21. PubMed
  58. M Wolters "Diet and psoriasis: experimental data and clinical evidence." The British journal of dermatology 153.4 (2006): 706-14. PubMed
  59. E Higgins "Alcohol, smoking and psoriasis." Clinical and experimental dermatology 25.2 (2000): 107-10. PubMed
  60. Luigi Naldi, Liliane Chatenoud, Dennis Linder, Anna Belloni Fortina, Andrea Peserico, Anna Rosa Virgili, Pier Luigi Bruni, Vito Ingordo, Giovanni Lo Scocco, Carmen Solaroli, Donatella Schena, Annalisa Barba, Anna Di Landro, Enrico Pezzarossa, Fabio Arcangeli, Claudia Gianni, Roberto Betti, Paolo Carli, Alessandro Farris, Gian Franco Barabino, Carlo La Vecchia "Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study." The Journal of investigative dermatology 125.1 (2005): 61-7. PubMed
  61. K Poikolainen, T Reunala, J Karvonen, J Lauharanta, P Kärkkäinen "Alcohol intake: a risk factor for psoriasis in young and middle aged men?" BMJ (Clinical research ed.) 300.6727 (1990): 780-3. PubMed
  62. B E Monk, S M Neill "Alcohol consumption and psoriasis." Dermatologica 173.2 (1987): 57-60. PubMed
  63. K Poikolainen, T Reunala, J Karvonen "Smoking, alcohol and life events related to psoriasis among women." The British journal of dermatology 130.4 (1994): 473-7. PubMed
  64. E M Higgins, A W du Vivier "Cutaneous disease and alcohol misuse." British medical bulletin 50.1 (1994): 85-98. PubMed
  65. Kresimir Kostoviu, Jasna Lipozenciu "Skin diseases in alcoholics." Acta dermatovenerologica Croatica : ADC 12.3 (2004): 181-90. PubMed
  66. G E Vincenti, S M Blunden "Psoriasis and alcohol abuse." Journal of the Royal Army Medical Corps 133.2 (1987): 77-8. PubMed
  67. H Tønnesen, A H Kaiser, B B Nielsen, A E Pedersen "Reversibility of alcohol-induced immune depression." British journal of addiction 87.7 (1992): 1025-8. PubMed
  68. H M Ockenfels, C Keim-Maas, R Funk, G Nussbaum, M Goos "Ethanol enhances the IFN-gamma, TGF-alpha and IL-6 secretion in psoriatic co-cultures." The British journal of dermatology 135.5 (1997): 746-51. PubMed
  69. A Farkas, L Kemény "Alcohol, liver, systemic inflammation and skin: a focus on patients with psoriasis." Skin pharmacology and physiology 26.3 (2014): 119-26. PubMed
  70. R E Schopf, H M Ockenfels, B Morsches "Ethanol enhances the mitogen-driven lymphocyte proliferation in patients with psoriasis." Acta dermato-venereologica 76.4 (1997): 260-3. PubMed
  71. C M Mills, E D Srivastava, I M Harvey, G L Swift, R G Newcombe, P J Holt, J Rhodes "Smoking habits in psoriasis: a case control study." The British journal of dermatology 127.1 (1992): 18-21. PubMed
  72. H C Williams "Smoking and psoriasis." BMJ (Clinical research ed.) 308.6926 (1994): 428-9. PubMed
  73. E M Farber, L Nall "An appraisal of measures to prevent and control psoriasis." Journal of the American Academy of Dermatology 10.3 (1984): 511-7. PubMed
  74. L Naldi, F Parazzini, L Peli, L Chatenoud, T Cainelli "Dietary factors and the risk of psoriasis. Results of an Italian case-control study." The British journal of dermatology 134.1 (1996): 101-6. PubMed
  75. E M Higgins, T J Peters, A W du Vivier "Smoking, drinking and psoriasis." The British journal of dermatology 129.6 (1994): 749-50. PubMed
  76. S A Grando, R M Horton, T M Mauro, D A Kist, T X Lee, M V Dahl "Activation of keratinocyte nicotinic cholinergic receptors stimulates calcium influx and enhances cell differentiation." The Journal of investigative dermatology 107.3 (1996): 412-8. PubMed
  77. J D Morrow, B Frei, A W Longmire, J M Gaziano, S M Lynch, Y Shyr, W E Strauss, J A Oates, L J Roberts "Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage." The New England journal of medicine 332.18 (1995): 1198-203. PubMed
  78. Houshang Nemati, Nemati Houshang, Reza Khodarahmi, Khodarahmi Reza, Masoud Sadeghi, Sadeghi Masoud, Ali Ebrahimi, Ebrahimi Ali, Mansour Rezaei, Rezaei Mansour, Asad Vaisi-Raygani "Antioxidant status in patients with psoriasis." Cell biochemistry and function 32.3 (2014): 268-273. PubMed
  79. Nicola Balato, Luisa Di Costanzo, Cataldo Patruno, Angela Patrì, Fabio Ayala "Effect of weather and environmental factors on the clinical course of psoriasis." Occupational and environmental medicine 70.8 (2013): 600. PubMed
  80. A R Mason, J M Mason, M J Cork, H Hancock, G Dooley "Topical treatments for chronic plaque psoriasis of the scalp: a systematic review." The British journal of dermatology 169.3 (2014): 519-27. PubMed
  81. E Castela, E Archier, S Devaux, A Gallini, S Aractingi, B Cribier, D Jullien, F Aubin, H Bachelez, P Joly, M Le Maître, L Misery, M-A Richard, C Paul, J P Ortonne "Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities." Journal of the European Academy of Dermatology and Venereology : JEADV 26 Suppl 3 (2012): 36-46. PubMed
  82. P C M van de Kerkhof, K Kragballe, S Segaert, M Lebwohl "Factors impacting the combination of topical corticosteroid therapies for psoriasis: perspectives from the International Psoriasis Council." Journal of the European Academy of Dermatology and Venereology : JEADV 25.10 (2012): 1130-9. PubMed
  83. J Mason, A R Mason, M J Cork "Topical preparations for the treatment of psoriasis: a systematic review." The British journal of dermatology 146.3 (2002): 351-64. PubMed
  84. D A Fisher "Adverse effects of topical corticosteroid use." The Western journal of medicine 162.2 (1995): 123-6. PubMed
  85. Arijit Coondoo, Meghana Phiske, Shyam Verma, Koushik Lahiri "Side-effects of topical steroids: A long overdue revisit." Indian dermatology online journal 5.4 (2014): 416-25. PubMed
  86. K Kragballe, B T Gjertsen, D De Hoop, T Karlsmark, P C van de Kerkhof, O Larkö, C Nieboer, J Roed-Petersen, A Strand, G Tikjøb "Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris." Lancet (London, England) 337.8735 (1991): 193-6. PubMed
  87. Justin R Sigmon, Brad A Yentzer, Steven R Feldman "Calcitriol ointment: a review of a topical vitamin D analog for psoriasis." The Journal of dermatological treatment 20.4 (2009): 208-12. PubMed
  88. P C van de Kerkhof "Biological activity of vitamin D analogues in the skin, with special reference to antipsoriatic mechanisms." The British journal of dermatology 132.5 (1995): 675-82. PubMed
  89. P C van de Kerkhof "An update on vitamin D3 analogues in the treatment of psoriasis." Skin pharmacology and applied skin physiology 11.1 (1998): 2-10. PubMed
  90. M Barna, J D Bos, M L Kapsenberg, F G Snijdewint "Effect of calcitriol on the production of T-cell-derived cytokines in psoriasis." The British journal of dermatology 136.4 (1997): 536-41. PubMed
  91. L Guenther, P C M Van de Kerkhof, E Snellman, K Kragballe, A C Chu, E Tegner, A Garcia-Diez, J Springborg "Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial." The British journal of dermatology 147.2 (2002): 316-23. PubMed
  92. K Kragballe, P M Steijlen, H H Ibsen, P C van de Kerkhof, J Esmann, L H Sorensen, M B Axelsen "Efficacy, tolerability, and safety of calcipotriol ointment in disorders of keratinization. Results of a randomized, double-blind, vehicle-controlled, right/left comparative study." Archives of dermatology 131.5 (1995): 556-60. PubMed
  93. A Pèrez, T C Chen, A Turner, R Raab, J Bhawan, P Poche, M F Holick "Efficacy and safety of topical calcitriol (1,25-dihydroxyvitamin d3) for the treatment of psoriasis." The British journal of dermatology 134.2 (1996): 238-46. PubMed
  94. P E Hutchinson, R Marks, J White "The efficacy, safety and tolerance of calcitriol 3 microg/g ointment in the treatment of plaque psoriasis: a comparison with short-contact dithranol." Dermatology (Basel, Switzerland) 201.2 (2000): 139-45. PubMed
  95. R G Shoss, L R Lumpkin "Current therapy of psoriasis." American family physician 15.1 (1977): 114-6. PubMed
  96. Jordan B Slutsky, Richard A F Clark, Alexander A Remedios, Peter A Klein "An evidence-based review of the efficacy of coal tar preparations in the treatment of psoriasis and atopic dermatitis." Journal of drugs in dermatology : JDD 9.10 (2010): 1258-64. PubMed
  97. Joshua A Zeichner "Use of Topical Coal Tar Foam for the Treatment of Psoriasis in Difficult-to-treat Areas." The Journal of clinical and aesthetic dermatology 3.9 (2011): 37-40. PubMed
  98. A B Fleischer, S R Feldman, S R Rapp, D M Reboussin, M L Exum, A R Clark "Alternative therapies commonly used within a population of patients with psoriasis." Cutis 58.3 (1997): 216-20. PubMed
  99. W H Liem, J L McCullough, G D Weinstein "Effectiveness of topical therapy for psoriasis: results of a national survey." Cutis 55.5 (1995): 306-10. PubMed
  100. C H Smith, K Jackson, S Chinn, K Angus, J N Barker "A double blind, randomized, controlled clinical trial to assess the efficacy of a new coal tar preparation (Exorex) in the treatment of chronic, plaque type psoriasis." Clinical and experimental dermatology 25.8 (2001): 580-3. PubMed
  101. Kapila V Paghdal, Robert A Schwartz "Topical tar: back to the future." Journal of the American Academy of Dermatology 61.2 (2009): 294-302. PubMed
  102. Alison McGill, Adrian Frank, Nicola Emmett, Douglas M Turnbull, Mark A Birch-Machin, Nick J Reynolds "The anti-psoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria." FASEB journal : official publication of the Federation of American Societies for Experimental Biology 19.8 (2006): 1012-4. PubMed
  103. N J Lowe, R E Ashton, H Koudsi, M Verschoore, H Schaefer "Anthralin for psoriasis: short-contact anthralin therapy compared with topical steroid and conventional anthralin." Journal of the American Academy of Dermatology 10.1 (1984): 69-72. PubMed
  104. Gerald D Weinstein, John Y M Koo, Gerald G Krueger, Mark G Lebwohl, Nicholas J Lowe, M Alan Menter, Deborah A Lew-Kaya, John Sefton, John R Gibson, Patricia S Walker "Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks." Journal of the American Academy of Dermatology 48.5 (2003): 760-7. PubMed
  105. M G Lebwohl, D L Breneman, B S Goffe, J R Grossman, M R Ling, J Milbauer, S H Pincus, R G Sibbald, L J Swinyer, G D Weinstein, D A Lew-Kaya, J C Lue, J R Gibson, J Sefton "Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis." Journal of the American Academy of Dermatology 39.4 Pt 1 (1998): 590-6. PubMed
  106. C Huber, E Christophers "“Keratolytic” effect of salicylic acid." Archives for dermatological research = Archiv fur dermatologische Forschung 257.3 (1977): 293-7. PubMed
  107. Tasleem Arif "Salicylic acid as a peeling agent: a comprehensive review." Clinical, cosmetic and investigational dermatology 8 (2015): 455-61. PubMed
  108. M Davies, R Marks "Studies on the effect of salicylic acid on normal skin." The British journal of dermatology 95.2 (1976): 187-92. PubMed
  109. M Lebwohl "The role of salicylic acid in the treatment of psoriasis." International journal of dermatology 38.1 (1999): 16-24. PubMed
  110. M Lebwohl, S Ali "Treatment of psoriasis. Part 1. Topical therapy and phototherapy." Journal of the American Academy of Dermatology 45.4 (2001): 487-98; quiz 499-502. PubMed
  111. R S Stern, R Lange "Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment." The Journal of investigative dermatology 91.2 (1988): 120-4. PubMed
  112. R S Stern, N Laird, J Melski, J A Parrish, T B Fitzpatrick, H L Bleich "Cutaneous squamous-cell carcinoma in patients treated with PUVA." The New England journal of medicine 310.18 (1984): 1156-61. PubMed
  113. M R Pittelkow, H O Perry, S A Muller, W Z Maughan, P C O'Brien "Skin cancer in patients with psoriasis treated with coal tar. A 25-year follow-up study." Archives of dermatology 117.8 (1981): 465-8. PubMed
  114. B K Armstrong, A Kricker "The epidemiology of UV induced skin cancer." Journal of photochemistry and photobiology. B, Biology 63.1-3 (2002): 8-18. PubMed
  115. M A Menter, J A See, W J Amend, C N Ellis, G G Krueger, M Lebwohl, W L Morison, J H Prystowsky, H H Roenigk, J L Shupack, A K Silverman, G D Weinstein, D E Yocum, M D Zanolli "Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994." Journal of the American Academy of Dermatology 34.2 Pt 1 (1996): 315-21. PubMed
  116. E L Speight, P M Farr "Calcipotriol improves the response of psoriasis to PUVA." The British journal of dermatology 130.1 (1994): 79-82. PubMed
  117. Monica Enamandram, Alexa B Kimball "Psoriasis epidemiology: the interplay of genes and the environment." The Journal of investigative dermatology 133.2 (2013): 287-9. PubMed
  118. B S Park, J I Youn "Factors influencing psoriasis: an analysis based upon the extent of involvement and clinical type." The Journal of dermatology 25.2 (1998): 97-102. PubMed
  119. Michael Zanolli "Phototherapy treatment of psoriasis today." Journal of the American Academy of Dermatology 49.2 Suppl (2004): S78-86. PubMed
  120. P Gisondi, G Altomare, F Ayala, F Bardazzi, L Bianchi, A Chiricozzi, A Costanzo, A Conti, P Dapavo, C De Simone, C Foti, L Naldi, A Offidani, A Parodi, S Piaserico, F Prignano, F Rongioletti, L Stingeni, M Talamonti, G Girolomoni "Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis." Journal of the European Academy of Dermatology and Venereology : JEADV 31.5 (2018): 774-790. PubMed
  121. Julia-Tatjana Maul, Vahid Djamei, Antonios G A Kolios, Barbara Meier, Justine Czernielewski, Pascal Jungo, Nikhil Yawalkar, Carlo Mainetti, Emmanuel Laffitte, Christina Spehr, Mark Anliker, Markus Streit, Matthias Augustin, Stephan Rustenbach, Curdin Conrad, Jürg Hafner, Wolf-Henning Boehncke, Luca Borradori, Michel Gilliet, Peter Itin, Lars E French, Peter Häusermann, Alexander A Navarini "Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT." Dermatology (Basel, Switzerland) 232.6 (2017): 640-647. PubMed
  122. J E Bernstein, L C Parish, M Rapaport, M M Rosenbaum, H H Roenigk "Effects of topically applied capsaicin on moderate and severe psoriasis vulgaris." Journal of the American Academy of Dermatology 15.3 (1986): 504-7. PubMed
  123. C N Ellis, B Berberian, V I Sulica, W A Dodd, M T Jarratt, H I Katz, S Prawer, G Krueger, I H Rex, J E Wolf "A double-blind evaluation of topical capsaicin in pruritic psoriasis." Journal of the American Academy of Dermatology 29.3 (1993): 438-42. PubMed
  124. T A Syed, S A Ahmad, A H Holt, S A Ahmad, S H Ahmad, M Afzal "Management of psoriasis with Aloe vera extract in a hydrophilic cream: a placebo-controlled, double-blind study." Tropical medicine & international health : TM & IH 1.4 (1996): 505-9. PubMed
  125. E Paulsen, L Korsholm, F Brandrup "A double-blind, placebo-controlled study of a commercial Aloe vera gel in the treatment of slight to moderate psoriasis vulgaris." Journal of the European Academy of Dermatology and Venereology : JEADV 19.3 (2005): 326-31. PubMed
  126. G Weber, K Galle "[The liver–a therapeutic target in dermatoses]." Die Medizinische Welt 34.4 (1983): 108-11. PubMed
  127. Shanu Kohli Kurd, Nana Smith, Abby VanVoorhees, Andrea B Troxel, Vladimir Badmaev, John T Seykora, Joel M Gelfand "Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial." Journal of the American Academy of Dermatology 58.4 (2008): 625-31. PubMed
Last Updated:
in Psoriasis   0

About Michael Anders

After being affected by seborrheic dermatitis, I have made it my goal to gather and organize all the information that has helped me in my journey.

Share Your Thoughts

(will not be published)

No Comments

Be the first to start a conversation